Lachlan Hanbury-Brown

Ryan Deschner

Andreas Argyrides

Joshua Schimmer

Louise Chen

Alexa Deemer

Roanna Clarissa Ruiz

Rodney Reeves

- ARS Pharmaceuticals is approximately **ten months** into the launch of Nefi, which commenced in **October**.  **[1671858_tx_381240_0]** 
- The company initiated a direct-to-consumer (DTC) campaign in **June**, with linear TV ads starting in **July**, resulting in a significant increase in aided awareness for Nefi from **20% to 49%**.  **[1671858_tx_381240_0]** **[1671858_tx_381240_3]** 
- To improve profitability, ARS Pharmaceuticals discontinued its GoodRx program in **July**, which had been leading to negative revenue, and is actively working to expand access by anticipating Nefi's inclusion on Prime's formulary by **January 1** and pressuring Caremark for similar coverage.  **[1671858_tx_381240_4]** **[1671858_tx_381240_7]** **[1671858_tx_381240_8]** 
- Physician adoption is growing, with approximately **10,000 doctors** having prescribed Nefi, and the company observes a higher preference for Nefi among children and a greater number of prescriptions per patient compared to injections.  **[1671858_tx_381240_1]** **[1671858_tx_381240_6]** 
- The average co-pay for Nefi with commercial coverage is **$37**, with about **80%** of commercially covered patients paying **$25 or less**, which is lower than the **$48** average for generic auto-injectors.  **[1671858_tx_381240_6]**

ARS Pharmaceuticals (SPRY)